Tag
Saroglitazar significantly improves liver fat content, liver enzymes, and lipid profiles in women with PCOS and MASLD, highlighting its potential as a therapeutic option in this underrepresented population.
Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and
Emerging evidence identifies KIF13B facilitating KPNA2-mediated nuclear import of PPARα as a critical mechanism to mitigate alcohol-associated liver steatosis, highlighting novel therapeutic strategies for ALD.
A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
This clinical trial evaluates chitosan supplementation’s impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.
A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may
